Schoerlin M P, Blouin R A, Pfefen J P, Guentert T W
Department of Clinical Pharmacology, F. Hoffmann-La Roche, Basel, Switzerland.
Acta Psychiatr Scand Suppl. 1990;360:98-100. doi: 10.1111/j.1600-0447.1990.tb05347.x.
A number of pharmacokinetics studies in which patients had been phenotyped and poor metabolizers for moclobemide found were analysed retrospectively. There were 27 subjects in all, aged between 19 and 75 years, and 5 of these were classified as poor debrisoquine metabolizers. Although there was a wide variability in the pharmacokinetic parameters observed, no consistent relationship was found between these and debrisoquine phenotype. Poor debrisoquine metabolizers all had values within the extremes for the efficient metabolism. This was true for both single and multiple dosing. This analysis is limited by the small number of subjects as well as its retrospective nature. Nevertheless, the data suggest that no deviations of moclobemide pharmacokinetics should be expected in poor metabolizers of debrisoquine compared with normal metabolizers.
回顾性分析了多项药代动力学研究，这些研究对患者进行了表型分析，并发现了吗氯贝胺的代谢不良者。总共有27名受试者，年龄在19至75岁之间，其中5人被归类为异喹胍代谢不良者。尽管观察到的药代动力学参数存在很大差异，但未发现这些参数与异喹胍表型之间存在一致关系。异喹胍代谢不良者的所有值都在高效代谢的极端范围内。单剂量和多剂量给药都是如此。该分析受到受试者数量少及其回顾性性质的限制。然而，数据表明，与正常代谢者相比，异喹胍代谢不良者的吗氯贝胺药代动力学预计不会有偏差。
